Catalio Capital Management
Latest statistics and disclosures from Catalio Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Avalyn Pharma, JNJ, GILD, BBIO, SNDX, and represent 34.76% of Catalio Capital Management's stock portfolio.
- Added to shares of these 10 stocks: Avalyn Pharma (+$55M), JNJ (+$35M), Parabilis Medicines (+$23M), GILD (+$13M), PTGX (+$13M), AXSM (+$11M), Kailera Therapeutics (+$10M), Odyssey Therapeutics (+$8.6M), ASND (+$8.5M), SEPN (+$8.1M).
- Started 11 new stock positions in BBOT, Kardigan Ord, JNJ, Kailera Therapeutics, FDMT, ASND, Avalyn Pharma, AXSM, Odyssey Therapeutics, PTGX. Parabilis Medicines.
- Reduced shares in these 10 stocks: DNTH (-$51M), Ascendis Pharma A S (-$30M), DFTX (-$22M), TERN (-$22M), Soleno Therapeutics (-$19M), BSX (-$19M), RARE (-$18M), MANE (-$16M), CYTK (-$14M), ADPT (-$10M).
- Sold out of its positions in ABVX, ADPT, Ascendis Pharma A S, BSX, CYTK, Kalvista Pharmaceuticals, PHAT, Soleno Therapeutics, SUPN, TERN. TYRA, NAMS, QURE.
- Catalio Capital Management was a net seller of stock by $-25M.
- Catalio Capital Management has $532M in assets under management (AUM), dropping by 11.15%.
- Central Index Key (CIK): 0001958125
Tip: Access up to 7 years of quarterly data
Positions held by Catalio Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Catalio Capital Management
Catalio Capital Management holds 39 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Avalyn Pharmaceuticals Com Shs | 10.4 | $55M | NEW | 1.7M | 32.92 |
|
| Johnson & Johnson (JNJ) | 6.6 | $35M | NEW | 139k | 253.97 |
|
| Gilead Sciences (GILD) | 6.4 | $34M | +64% | 269k | 126.34 |
|
| Bridgebio Pharma (BBIO) | 6.4 | $34M | +5% | 455k | 74.48 |
|
| Syndax Pharmaceuticals (SNDX) | 5.0 | $27M | +16% | 1.2M | 21.86 |
|
| Definium Therapeutics Com Shs (DFTX) | 5.0 | $27M | -45% | 563k | 47.04 |
|
| Bristol Myers Squibb (BMY) | 4.5 | $24M | 413k | 57.62 |
|
|
| Parabilis Medicines | 4.2 | $23M | NEW | 824k | 27.37 |
|
| Natera (NTRA) | 4.2 | $22M | +15% | 82k | 271.45 |
|
| Incyte Corporation (INCY) | 4.1 | $22M | +5% | 192k | 113.36 |
|
| Septerna (SEPN) | 3.4 | $18M | +82% | 536k | 33.49 |
|
| Mineralys Therapeutics (MLYS) | 3.3 | $18M | +47% | 649k | 26.98 |
|
| Heartflow Inc/Sh (HTFL) | 3.2 | $17M | +44% | 583k | 29.34 |
|
| Corvus Pharmaceuticals (CRVS) | 3.0 | $16M | +21% | 1.1M | 14.94 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 2.8 | $15M | +8% | 277k | 53.67 |
|
| Protagonist Therapeutics (PTGX) | 2.5 | $13M | NEW | 107k | 122.58 |
|
| Disc Medicine (IRON) | 2.2 | $12M | +29% | 159k | 73.14 |
|
| Edwards Lifesciences (EW) | 2.1 | $11M | -13% | 125k | 90.46 |
|
| Axsome Therapeutics (AXSM) | 2.0 | $11M | NEW | 43k | 244.77 |
|
| Ultragenyx Pharmaceutical (RARE) | 2.0 | $11M | -62% | 316k | 33.39 |
|
| Kailera Therapeutics Common Stock | 1.9 | $10M | NEW | 469k | 22.03 |
|
| Karyopharm Therapeutics Com New (KPTI) | 1.7 | $9.2M | +4% | 941k | 9.77 |
|
| Odyssey Therapeutics Common Stock | 1.6 | $8.6M | NEW | 458k | 18.71 |
|
| Ascendis Pharma A/s Ord Shs (ASND) | 1.6 | $8.5M | NEW | 32k | 266.72 |
|
| Kardigan Ord | 1.4 | $7.5M | NEW | 313k | 23.85 |
|
| Eledon Pharmaceuticals (ELDN) | 1.3 | $6.7M | +3% | 1.7M | 3.94 |
|
| 4d Molecular Therapeutics In (FDMT) | 1.2 | $6.3M | NEW | 471k | 13.30 |
|
| Veradermics Common Stock (MANE) | 1.1 | $5.6M | -73% | 46k | 122.94 |
|
| Dyne Therapeutics (DYN) | 1.0 | $5.4M | -13% | 245k | 22.21 |
|
| Fractyl Health (GUTS) | 0.9 | $4.9M | +12% | 6.2M | 0.79 |
|
| Immunocore Hldgs Ads (IMCR) | 0.9 | $4.7M | +75% | 148k | 31.75 |
|
| Dianthus Therapeutics (DNTH) | 0.6 | $3.2M | -94% | 33k | 97.48 |
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 0.5 | $2.4M | NEW | 318k | 7.62 |
|
| Protara Therapeutics Com Stk (TARA) | 0.4 | $2.0M | -10% | 520k | 3.82 |
|
| Hyperfine Com Cl A (HYPR) | 0.3 | $1.8M | 1.3M | 1.35 |
|
|
| Ataibeckley Com Shs (ATAI) | 0.2 | $1.0M | 197k | 5.27 |
|
|
| Metagenomi (MGX) | 0.1 | $630k | 529k | 1.19 |
|
|
| Outset Med Com New (OM) | 0.1 | $511k | 118k | 4.32 |
|
|
| Faeth Therapeutics Com New (FTH) | 0.1 | $368k | 15k | 25.00 |
|
Past Filings by Catalio Capital Management
SEC 13F filings are viewable for Catalio Capital Management going back to 2025
- Catalio Capital Management 2025 Q4 restated filed Sept. 2, 2026
- Catalio Capital Management 2026 Q2 filed Aug. 14, 2026
- Catalio Capital Management 2026 Q1 filed May 15, 2026
- Catalio Capital Management 2025 Q4 filed Feb. 17, 2026
- Catalio Capital Management 2025 Q3 filed Nov. 14, 2025